Journal of Clinical Oncology, Vol 10, 647-656, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

EK Rowinsky, LB Grochow, CB Hendricks, DS Ettinger, AA Forastiere, LA Hurowitz, WP McGuire, SE Sartorius, BG Lubejko and SH Kaufmann
Johns Hopkins Oncology Center, Division of Pharmacology and Experimental Therapeutics, Baltimore, MD 21205.

PURPOSE: A phase I and pharmacologic study was undertaken to determine the maximum-tolerated dose (MTD), describe the principal toxicities, and characterize the pharmacologic behavior of topotecan, which is a semisynthetic analog of camptothecin with broad preclinical antitumor activity and the first topoisomerase I-targeting agent to enter clinical development in the United States since studies of sodium camptothecin over 2 decades ago. PATIENTS AND METHODS: Thirty-minute infusions of topotecan were administered daily for 5 consecutive days every 3 weeks to patients with advanced solid malignancies at doses ranging from 0.5 to 2.5 mg/m2/d. RESULTS: At doses of 1.5 and 2.0 mg/m2, grade 3 and 4 neutropenia occurred in most courses; however, neutropenia was brief and rarely associated with fevers or treatment delays. Neutropenia was more severe in patients with extensive prior treatment than in minimally pretreated patients, but these differences were not substantial. At 2.5 mg/m2, topotecan induced profound and prolonged neutropenia that was frequently associated with fever and treatment delays in minimally pretreated patients. Topotecan also induced mild depressions in the hematocrit level in the majority of courses; however, precipitous drops requiring transfusional therapy occurred in 14% of courses and suggested a drug-induced hemolytic effect. Unlike sodium camptothecin, hemorrhagic cystitis was not observed. Thrombocytopenia, skin rash, diarrhea, and vomiting occurred infrequently and were modest in severity. Responses were observed in non-small-cell lung carcinoma and platinum-refractory ovarian carcinoma. Drug disposition in plasma was described by a biexponential model, with renal elimination accounting for 38.7% of drug disposition. Topotecan was rapidly hydrolyzed in vivo to a less active, open-ring form. CONCLUSIONS: Neutropenia is the dose-limiting toxicity, and 1.5 mg/m2 is the recommended starting dose of topotecan for both minimally and heavily pretreated patients in future phase II trials, with escalation to 2.0 mg/m2 if treatment is well tolerated. Non-small-cell lung and platinum-refractory ovarian carcinomas should be among those evaluated in phase II trials of topotecan.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Le Tourneau, J. J. Lee, and L. L. Siu Dose Escalation Methods in Phase I Cancer Clinical Trials J Natl Cancer Inst, May 20, 2009; 101(10): 708 - 720. [Abstract] [Full Text] [PDF]

				D. P. Lee, J. M. Skolnik, and P. C. Adamson Pediatric Phase I Trials in Oncology: An Analysis of Study Conduct Efficiency J. Clin. Oncol., November 20, 2005; 23(33): 8431 - 8441. [Abstract] [Full Text] [PDF]

				A. Chatterjee, R. Digumarti, R. N. V. S. Mamidi, K. Katneni, V. V. Upreti, A. Surath, M. L. Srinivas, S. Uppalapati, S. Jiwatani, S. Subramaniam, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of an Orally Active Novel Camptothecin Analog, DRF-1042, in Refractory Cancer Patients in a Phase I Dose Escalation Study J. Clin. Pharmacol., July 1, 2004; 44(7): 723 - 736. [Abstract] [Full Text] [PDF]

				N. C. Daw, V. M. Santana, L. C. Iacono, W. L. Furman, D. R. Hawkins, P. J. Houghton, J. C. Panetta, A. J. Gajjar, and C. F. Stewart Phase I and Pharmacokinetic Study of Topotecan Administered Orally Once Daily for 5 Days for 2 Consecutive Weeks to Pediatric Patients With Refractory Solid Tumors J. Clin. Oncol., March 1, 2004; 22(5): 829 - 837. [Abstract] [Full Text] [PDF]

				D. K. Armstrong Topotecan Dosing Guidelines in Ovarian Cancer: Reduction and Management of Hematologic Toxicity Oncologist, February 1, 2004; 9(1): 33 - 42. [Abstract] [Full Text] [PDF]

				S. Wadler, D. E. Levy, S. T. Lincoln, G. S. Soori, J. C. Schink, and G. Goldberg Topotecan Is an Active Agent in the First-Line Treatment of Metastatic or Recurrent Endometrial Carcinoma: Eastern Cooperative Oncology Group Study E3E93 J. Clin. Oncol., June 1, 2003; 21(11): 2110 - 2114. [Abstract] [Full Text] [PDF]

				S. N. Sanghavi, M. N. Needle, M. D. Krailo, J. R. Geyer, J. Ater, and M. P. Mehta A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: First report of the Children's Cancer Group-0952 Neuro-oncol, January 1, 2003; 5(1): 8 - 13. [Abstract] [PDF]

				M. Zamai, M. vandeVen, M. Farao, E. Gratton, A. Ghiglieri, M. G. Castelli, E. Fontana, R. d'Argy, A. Fiorino, E. Pesenti, et al. Camptothecin Poly[N-(2-Hydroxypropyl) Methacrylamide] Copolymers in Antitopoisomerase-I Tumor Therapy: Intratumor Release and Antitumor Efficacy Mol. Cancer Ther., January 1, 2003; 2(1): 29 - 40. [Abstract] [Full Text] [PDF]

				S. D. Baker, J. Verweij, E. K. Rowinsky, R. C. Donehower, J. H. M. Schellens, L. B. Grochow, and A. Sparreboom Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991-2001 J Natl Cancer Inst, December 18, 2002; 94(24): 1883 - 1888. [Abstract] [Full Text] [PDF]

				M. J. Guarino, C. J. Schneider, S. S. Grubbs, D. D. Biggs, A. L. Himelstein, K. Hogaboom, and S. Tilak A Dose-Escalation Study of Weekly Topotecan, Cisplatin, and Gemcitabine Front-Line Therapy in Patients with Inoperable Non-Small Cell Lung Cancer Oncologist, December 1, 2002; 7(6): 509 - 515. [Abstract] [Full Text] [PDF]

				R. L. Coleman Emerging Role of Topotecan in Front-Line Treatment of Carcinoma of the Ovary Oncologist, October 1, 2002; 7(90005): 46 - 55. [Abstract] [Full Text] [PDF]

				E. K. Rowinsky Weekly Topotecan: An Alternative to Topotecan's Standard Daily x 5 Schedule? Oncologist, August 1, 2002; 7(4): 324 - 330. [Abstract] [Full Text] [PDF]

				W. L. Furman, C. F. Stewart, M. Kirstein, J. L. Kepner, M. L. Bernstein, F. Kung, T. J. Vietti, C. P. Steuber, D. L. Becton, S. Baruchel, et al. Protracted Intermittent Schedule of Topotecan in Children With Refractory Acute Leukemia: A Pediatric Oncology Group Study J. Clin. Oncol., March 15, 2002; 20(6): 1617 - 1624. [Abstract] [Full Text] [PDF]

				M. V. Seiden, S.-W. Ng, J. G. Supko, D. P. Ryan, J. W. Clark, T. Lynch, K.-C. Huang, D. Kwiatkowski, A. Skarin, and J. P. Eder Jr. A Phase I Clinical Trial of Sequentially Administered Doxorubicin and Topotecan in Refractory Solid Tumors Clin. Cancer Res., March 1, 2002; 8(3): 691 - 697. [Abstract] [Full Text] [PDF]

				U. H. Athale, C. Stewart, J. F. Kuttesch, A. Moghrabi, W. Meyer, C. Pratt, A. Gajjar, and R. L. Heideman Phase I Study of Combination Topotecan and Carboplatin in Pediatric Solid Tumors J. Clin. Oncol., January 1, 2002; 20(1): 88 - 95. [Abstract] [Full Text] [PDF]

				W. C. Zamboni, D. Z. D'Argenio, C. F. Stewart, T. MacVittie, B. J. Delauter, A. M. Farese, D. M. Potter, N. M. Kubat, D. Tubergen, and M. J. Egorin Pharmacodynamic Model of Topotecan-induced Time Course of Neutropenia Clin. Cancer Res., August 1, 2001; 7(8): 2301 - 2308. [Abstract] [Full Text] [PDF]

				J. E. Janik, L. L. Miller, E. L. Korn, D. Stevens, B. D. Curti, J. W. Smith II, M. Sznol, K. C. Conlon, W. Sharfman, W. J. Urba, et al. A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma Blood, April 1, 2001; 97(7): 1942 - 1946. [Abstract] [Full Text] [PDF]

				M. E. Royce, P. M. Hoff, P. Dumas, Y. Lassere, J. J. Lee, J. Coyle, M. P. Ducharme, R. De Jager, and R. Pazdur Phase I and Pharmacokinetic Study of Exatecan Mesylate (DX-8951f): A Novel Camptothecin Analog J. Clin. Oncol., March 1, 2001; 19(5): 1493 - 1500. [Abstract] [Full Text] [PDF]

				B. J. Fisher, C. Scott, D. R. Macdonald, C. Coughlin, and W. J. Curran Phase I Study of Topotecan Plus Cranial Radiation for Glioblastoma Multiforme: Results of Radiation Therapy Oncology Group Trial 9507 J. Clin. Oncol., February 15, 2001; 19(4): 1111 - 1117. [Abstract] [Full Text] [PDF]

				V. Boige, E. Raymond, S. Faivre, M. Gatineau, K. Meely, S. Mekhaldi, P. Pautier, M. Ducreux, O. Rixe, and J.-P. Armand Phase I and Pharmacokinetic Study of the Camptothecin Analog DX-8951f Administered as a 30-Minute Infusion Every 3 Weeks in Patients With Advanced Cancer J. Clin. Oncol., December 1, 2000; 18(23): 3986 - 3992. [Abstract] [Full Text] [PDF]

				D. L. Emerson, R. Bendele, E. Brown, S. Chiang, J. P. Desjardins, L. C. Dihel, S. C. Gill, M. Hamilton, J. D. LeRay, L. Moon-McDermott, et al. Antitumor Efficacy, Pharmacokinetics, and Biodistribution of NX 211: A Low-Clearance Liposomal Formulation of Lurtotecan Clin. Cancer Res., July 1, 2000; 6(7): 2903 - 2912. [Abstract] [Full Text]

				J. M. Gallo, P. B. Laub, E. K. Rowinsky, L. B. Grochow, and S. D. Baker Population Pharmacokinetic Model for Topotecan Derived From Phase I Clinical Trials J. Clin. Oncol., June 12, 2000; 18(12): 2459 - 2467. [Abstract] [Full Text] [PDF]

				K. Kelly New Chemotherapy Agents for Small Cell Lung Cancer Chest, April 1, 2000; 117 (2009): 156S - 162S. [Abstract] [Full Text] [PDF]

				S. C. White, S. Cheeseman, N. Thatcher, H. Anderson, B. Carrington, S. Hearn, G. Ross, and M. Ranson Phase II Study of Oral Topotecan in Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., March 1, 2000; 6(3): 868 - 873. [Abstract] [Full Text]

				H. Frangoul, M. M. Ames, R. B. Mosher, J. M. Reid, M. D. Krailo, N. L. Seibel, D. W. W. Shaw, P. G. Steinherz, J. A. Whitlock, and J. S. Holcenberg Phase I Study of Topotecan Administered as a 21-Day Continuous Infusion in Children with Recurrent Solid Tumors: A Report from the Children's Cancer Group Clin. Cancer Res., December 1, 1999; 5(12): 3956 - 3962. [Abstract] [Full Text] [PDF]

				I. Kramer and J. Thiesen Stability of topotecan infusion solutions in polyvinylchloride bags and elastomeric portable infusion devices Journal of Oncology Pharmacy Practice, June 1, 1999; 5(2): 75 - 82. [Abstract] [PDF]

				V. M.M. Herben, R. van Gijn, J. H.M. Schellens, M. Schot, J. Lieverst, M. J.X. Hillebrand, N. E. Schoemaker, M. G. Porro, J. H. Beijnen, and W. W. ten Bokkel Huinink Phase I and Pharmacokinetic Study of a Daily Times 5 Short Intravenous Infusion Schedule of 9-Aminocamptothecin in a Colloidal Dispersion Formulation in Patients With Advanced Solid Tumors J. Clin. Oncol., June 1, 1999; 17(6): 1906 - 1906. [Abstract] [Full Text] [PDF]

				C. J. H. Gerrits, J. H. M. Schellens, H. Burris, J. R. Eckardt, A. S. T. Planting, M. E. L. van der Burg, G. I. Rodriguez, W. J. Loos, V. van Beurden, I. Hudson, et al. A Comparison of Clinical Pharmacodynamics of Different Administration Schedules of Oral Topotecan (Hycamtin) Clin. Cancer Res., January 1, 1999; 5(1): 69 - 75. [Abstract] [Full Text] [PDF]

				J.-F. Héron Topotecan: An Oncologist's View Oncologist, December 1, 1998; 3(6): 390 - 402. [Abstract] [Full Text]

				S. Winter and M. Weller Potentiation of CD95L-Induced Apoptosis of Human Malignant Glioma Cells by Topotecan Involves Inhibition of RNA Synthesis but Not Changes in CD95 or CD95L Protein Expression J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1374 - 1382. [Abstract] [Full Text]

				D. Armstrong and S. O'Reilly Clinical Guidelines for Managing Topotecan-Related Hematologic Toxicity Oncologist, February 1, 1998; 3(1): 4 - 10. [Abstract] [Full Text]

				V. Relias and J. Andrew Skirvin Review : Topoisomerase I inhibitors: 1. Topotecan Journal of Oncology Pharmacy Practice, December 1, 1997; 3(4): 173 - 185. [Abstract] [PDF]

				Media Review: References of Interest for the Pediatric Oncology Nurse Journal of Pediatric Oncology Nursing, January 1, 1992; 9(4): 196 - 198. [PDF]